About this episode

The episode discusses a study on the effectiveness of sacituzumab govitecan combined with pembrolizumab for treating metastatic PD-L1 positive triple-negative breast cancer.

CHICAGO, USA—Combining the antibody-drug conjugate sacituzumab govitecan with pembrolizumab immunotherapy for patients with metastatic triple-negative breast cancers testing positive for the programmed death-ligand 1 (PD-L1) led to significant delays of disease progression after subsequent therapy in comparison with standard of care using a combination of chemotherapy with pembrolizumab. That’s according to first author of research reported at the 2026 American Association of Clinical Oncology Annual Meeting Kevin Kalinsky MD, Division Director of Breast Medical Oncology from Emory University at the Winship Cancer Institute, Hematology and Medical Oncology, in Atlanta, USA. He told reporter Peter Goodwin more about the details.

People in this episode

Guest: Kevin Kalinsky MD

Topics covered

• oncology
• breast cancer
• immunotherapy
• clinical research
• ASCO 2026
• metastatic cancer
• PD-L1

Keywords

• sacituzumab govitecan
• pembrolizumab
• triple-negative breast cancer
• metastatic cancer
• PD-L1
• ASCO 2026
• disease progression

Mentioned in this episode

Organizations: Emory University, Winship Cancer Institute, American Association of Clinical Oncology

Products: sacituzumab govitecan, pembrolizumab

Places: Chicago, USA, Atlanta, USA

More episodes of Audio Journal of Oncology Podcast

• Wing-Lok Chan MBBS; 2026 ASCO: Patients with Advanced Cancer Using The SUPPORT+ Mobile Phone App With Nurse Supervision have Better Quality of Life and Fewer Hospitalizations · July 8, 2026 · 9 min
• Ghassan K. Abou-Alfa MD PhD; ASCO 2026: Adding Doublet Immune Checkpoint Inhibition to Embolization with or without anti-Growth Factor TKI Therapy Extends Progression Free Survival in Patients with Hepatocellular Cancer · June 30, 2026 · 9 min
• Jonathan W. Goldman MD and David R Spigel MD; ASCO 2026: Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results · June 23, 2026 · 10 min
• Mark A Dickson, ASCO 2026: Abemaciclib Brings Marked Increase in Progression Free Survival for Patients with Advanced Dedifferentiated Liposarcoma · June 15, 2026 · 7 min
• Jana de Boniface MD PhD; ASCO 2026: Omitting Axillary Lymph Node Dissection is Safe for Patients with Breast Cancer Macrometastases to One or Two Sentinel Lymph Nodes · June 11, 2026 · 7 min
• Jean-Marc Classe, MD PhD; ASCO 2026: Timing of Surgery for Advanced Ovarian Cancer among Neoadjuvant and Adjuvant Chemotherapy Cycles: Early Findings from Randomized CHRONO Trial · June 9, 2026 · 9 min

Explore listener stats, chart rankings, contacts and more on the Audio Journal of Oncology Podcast podcast page.